PledPharma AB (publ) Stock Nasdaq Stockholm
Equities
SE0003815604
Biotechnology & Medical Research
Sales 2024 * | 65.08M 5.98M | Sales 2025 * | 471M 43.28M | Capitalization | 1.74B 160M |
---|---|---|---|---|---|
Net income 2024 * | -291M -26.74M | Net income 2025 * | 105M 9.65M | EV / Sales 2024 * | 28.3 x |
Net Debt 2024 * | 103M 9.43M | Net cash position 2025 * | 61.97M 5.69M | EV / Sales 2025 * | 3.56 x |
P/E ratio 2024 * |
-6.25
x | P/E ratio 2025 * |
8.69
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 | |
Thomas Lönngren
CHM | Chairman | 73 | 21-03-31 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.38% | 22.02B | |
-17.84% | 20.9B | |
-9.35% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |